vTv Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTVT research report →
Range $42 – $42
Price Chart
About the company
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes.
- CEO
- Paul J. Sekhri
- IPO
- 2015
- Employees
- 26
- HQ
- High Point, NC, US
Get TickerSpark's AI analysis on VTVT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $61.33M
- P/E
- 517.00
- PEG
- -0.21
- P/S
- 1.66
- P/B
- 2.77
- EV/EBITDA
- 1.87
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -29.80%
- Net Margin
- -20.84%
- ROE
- -10.15%
- ROIC
- -15.34%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-32,808,000
- Net Income
- $-26,974,000-46.1%
- EPS
- $-3.20+0.0%
- OCF Growth
- +0.2%
- FCF Growth
- +0.2%
- 52W High
- $44.00
- 52W Low
- $15.47
- 50D MA
- $26.77
- 200D MA
- $32.47
- Beta
- 0.26
- RSI (14)
- 17
- Avg Volume
- 33.32K
No earnings-call transcripts are available for VTVT yet.
- Free Float
- 52.1%
- Shares Outstanding
- 3.95M
- Float Shares
- 2.06M
of shares held by institutions
44 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Samsara Biocapital, LLC | 354.73K | ▲ 56.23K |
| Millennium Management LLC | 342.48K | ▲ 72.61K |
| Fmr LLC | 260.39K | 0 |
| Siren, L.L.C. | 163.00K | 0 |
| Baker Bros. Advisors LP | 148.31K | 0 |
| Vanguard Group Inc | 83.40K | ▲ 36.41K |
| Vanguard Capital Management LLC | 81.74K | ▼ 12.72K |
| Trails Edge Capital Partners, LP | 76.99K | ▼ 8.20K |
| Aisling Capital Management LP | 58.77K | ▲ 8.78K |
| Two Sigma Investments, LP | 47.65K | ▲ 36.17K |
| Geode Capital Management, LLC | 24.35K | ▼ 8.12K |
| Hrt Financial LP | 24.17K | ▲ 18.24K |
Held by 28 ETFs
Biggest fund positions in VTVT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | BAKER BROS. ADVISORS LP | other | 6,000 |
| Jun 26, 26 | SPIEGELMAN DANIEL K | other | 6,000 |
| Jun 26, 26 | AKKARAJU SRINIVAS | other | 6,000 |
| Jun 26, 26 | Al-Marzooqi Fahed | other | 6,000 |
| Jun 26, 26 | Phillips Anne M. | other | 6,000 |
| Feb 17, 26 | Tung Michael Stephen | other | 44,969 |
| Feb 17, 26 | SEKHRI PAUL J | other | 140,000 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 983,214 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 877,214 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 106,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VTVT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VTVT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
globenewswire.com · Oct 27
vTv Therapeutics Inc. (VTVT) Discusses Hypoglycemia Burden in Type 1 Diabetes and Cadisegliatin Phase 3 Program Transcript
seekingalpha.com · Oct 20
vTv Therapeutics Highlights Cadisegliatin's Phase III Push to Tackle Type 1 Hypoglycemia
marketbeat.com · Oct 20
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
globenewswire.com · Oct 7
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
globenewswire.com · Oct 6
Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT)
defenseworld.net · Oct 5
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
globenewswire.com · Oct 5
Theravance Biopharma (NASDAQ:TBPH) versus vTv Therapeutics (NASDAQ:VTVT) Head-To-Head Contrast
defenseworld.net · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
